-0.06 | -1.37%
| Price and Volume | |
|---|---|
| Recent Price | 4.39 |
| 52 Week High | 7.29 |
| 52 Week Low | 2.90 |
| Avg. Daily Vol. (Mil) | 0.21 |
| Beta (3 year) | 0.89 |
| Share Related Items | |
| Mkt Cap (Mil) | 135.41 |
| Shares Out (Mil) | 30.85 |
| Float (Mil) | 25.50 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 4.00 |
| Current Ratio | 5.80 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | 0.00 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 5.77 |
| Price/Book | 1.97 |
| Price/Cash Flow | -400.00 |
| Per Share Data | |
| Earnings | -0.05 |
| Sales | 0.76 |
| Book Value | 2.23 |
| Cash Flow | -0.01 |
| Business Summary | |
|---|---|
| A biopharmaceutical company, focused primarily on the development of novel therapeutics for radiology and neuropsychiatry. | |
| General Information | |
| 41 Seyon Street Building 1
Suite 100 Waltham, MA 02453 |
|
| www.repligen.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 137 | |
| CEO: Dr. Walter C. Herlihy,Ph | |
| Short Interest | |
| Current Month (Mil) | 0.55 |
| Previous Month (Mil) | 0.19 |
| Short Interest Ratio (Days) | 1.70 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | 0.00 |
| Return on Investments | n.a. |
| Profitability | |
| Gross Margin | n.a. |
| EBIT Margin | n.a. |
| Profit Margin | -6.90 |
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note |
|
|---|---|---|---|---|
| 12,445.56 | 1,316.58 | 2,837.60 | 16.41 |
Oil *
103.70
|
|
DOWN
135.13 |
DOWN
15.84 |
DOWN
33.39 |
DOWN
0.90 |
10 Yr
1.64%
SPDR Gold
150.52
|
|
-1.07%
|
-1.19%
|
-1.16%
|
-5.20%
|
Data delayed 20 minutes |
Connect with TheStreet